Fig. 3
From: Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy
Germline gene ablation of Nr2f6 in combination with established CTLA-4 immune checkpoint blockade. a Schematic overview of tumor injection and immune checkpoint blockade therapy. b, d Tumor growth curve of wildtype and Nr26−/− mice that received the high dose of 5 × 105 B16-OVA melanoma cells subcutaneously and were treated either with “mono-therapies” of genetic Nr2f6 deficiency (green, D – second graph, p = 0.0037) or CTLA-4 blockade in wildtype mice (dashed black, D – third graph, p = 0.0037) or IgG control antibody (black – wildtype, D – first graph) or with a combination of Nr2f6 loss and CTLA-4 blockade (dashed red, D – fourth graph, p = 0.047). c Survival analysis using a Kaplan Meier plot of wildtype and Nr2f6−/− mice treated either with IgG control or CTLA-4 blocking antibody (p < 0.0001) showing 3/5 long-term survivor mice in the combinatorial therapy group of Nr2f6−/− mice vs. 2/8 survivors in the corresponding control wildtype group. Results shown are derived from at least two independent experiments